-
Capital, M&A & Industry Strategy6 days agoRoche flags ‘final opportunity’ for Germany to reestablish as a reliable investment location
Following the withdrawal of billions of dollars in investments from Boehringer Ingelheim and Eli Lilly, German lawmakers have proposed a clause to the country’s healthcare reforms...
-
Capital, M&A & Industry Strategy6 days agoSTAT+: Treasury proposes major restrictions to U.S. investment in Chinese biotech sector
A new Treasury Department proposal would restrict U.S. investments in Chinese biotechs, but still allows licensing deals.
-
Capital, M&A & Industry Strategy6 days agoUS explores China biotech restrictions, exempts licensing deals
A new proposal from the U.S. government seeking to address investment in Chinese biotech as a matter of national security drew cautious statements from across the...
-
Capital, M&A & Industry Strategy6 days agoDraft U.S. outbound investment rule could chill cross-border collaboration
BIOCENTURY | POLITICS, POLICY & LAWDRAFT U.S. OUTBOUND INVESTMENT RULE COULD CHILL CROSS-BORDER COLLABORATIONProposed COINS Act implementing rule allows licensing Chinese drugs, but seeks to limit...
-
Capital, M&A & Industry Strategy6 days agoProtein degrader specialist Lycia prices $318M IPO
Funds from the upsized offering will support a trio of protein-degrading medicines in development for allergic conditions as well as the autoimmune disorder Graves’ disease.
-
Capital, M&A & Industry Strategy7 days agoEQT to Acquire Qiagen for $12.1B, Plans to Take Tools, Diagnostics Provider Private
EQT has €354 billion in assets under management and a three-decade track record of acquiring, developing, and sometimes selling companies that include life sciences tools/tech concerns....
-
Capital, M&A & Industry Strategy7 days agoSTAT+: Will the Treasury restrict U.S. investment in the Chinese biotech sector?
Rumors are swirling that the Treasury Department this week is going to propose a rule that restricts U.S. investment in the Chinese biotech sector.
-
Capital, M&A & Industry Strategy7 days agoBiotech notches 31 IPOs already this year, with 4 more joining queue
The sector’s IPO tally has surpassed each of the past four years, with four October debuts adding momentum—but activity still remains well below the COVID-19 boom...
-
Capital, M&A & Industry Strategy7 days agoSTAT+: Pharmalittle: We’re reading about a U.S. rule on Chinese deals, Belgium refusing Mounjaro coverage, and more
U.S. is poised to issue a proposed rule that would subject outbound licensing deals with Chinese biotech companies to additional scrutiny
-
Capital, M&A & Industry Strategy7 days agoWhy investors are taking another look at kidney disease
In this episode of Denatured, you’ll hear from Bruce Culleton, CEO at ProKidney and Demetri Maxim, CEO at Nephrogen. We discuss why kidney disease has long...
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
